Taxotere Patent Expiration

Taxotere is a drug owned by Sanofi Aventis Us Llc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 22, 2014. Details of Taxotere's patents and their expiration are given in the table below.

Filter patents by

NEW
Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5438072

(Pediatric)

Taxoid-based compositions
May, 2014

(12 years ago)

Expired
US5438072 Taxoid-based compositions
Nov, 2013

(12 years ago)

Expired
US5714512

(Pediatric)

Compositions containing taxane derivatives
Jan, 2013

(13 years ago)

Expired
US5750561

(Pediatric)

Compositions containing taxane derivatives
Jan, 2013

(13 years ago)

Expired
US5698582

(Pediatric)

Compositions containing taxane derivatives
Jan, 2013

(13 years ago)

Expired
US5698582 Compositions containing taxane derivatives
Jul, 2012

(14 years ago)

Expired
US5714512 Compositions containing taxane derivatives
Jul, 2012

(14 years ago)

Expired
US5750561 Compositions containing taxane derivatives
Jul, 2012

(14 years ago)

Expired


FDA has granted several exclusivities to Taxotere. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Taxotere, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Taxotere.

Exclusivity Information

Taxotere holds 2 exclusivities. All of its exclusivities have expired in 2013. Details of Taxotere's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
M(M-61) May 13, 2013
Pediatric Exclusivity(PED) Nov 13, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Taxotere is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Taxotere's family patents as well as insights into ongoing legal events on those patents.

Taxotere's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Clinical Trials

Recent Clinical Trials on Taxotere:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer National Cancer Institute (NCI) NA NOT YET RECRUITING
(Sep 11, 2026)
PHASE1, PHASE2
Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer Centre Oscar Lambret NA COMPLETED
(Sep 1, 2026)
PHASE2
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma Peking University NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC OncoC4, Inc. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy ECOG-ACRIN Cancer Research Group NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade Emory University NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Memorial Sloan Kettering Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer National Cancer Institute (NCI) NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) AbbVie NA RECRUITING
(Sep 1, 2026)
PHASE3
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Novartis Pharmaceuticals NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
Intravesical BCG vs GEMDOCE in NMIBC ECOG-ACRIN Cancer Research Group NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Yu jiren NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Hospital Centre Biel/Bienne NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
A Study of KK2269 in Adult Participants With Solid Tumors Kyowa Kirin Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE1
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer BioNTech SE NA RECRUITING
(Sep 1, 2026)
PHASE3
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) Genmab NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE2
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer University Health Network, Toronto NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Merck Sharp & Dohme LLC NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) Pfizer NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer Hoffmann-La Roche NA RECRUITING
(Sep 1, 2026)
PHASE2
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer BioNTech SE NA RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation Astellas Pharma Global Development, Inc. NA RECRUITING
(Sep 1, 2026)
PHASE3
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction Yongxu Jia NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2
A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer AbbVie NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma The First Affiliated Hospital of Zhengzhou University NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy Mabwell (Shanghai) Bioscience Co., Ltd. NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE3
Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer Gustave Roussy, Cancer Campus, Grand Paris NA TERMINATED
(Aug 1, 2026)
PHASE2
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies Genentech, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER) Ruijin Hospital NA TERMINATED
(Aug 1, 2026)
PHASE2
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer Astellas Pharma Global Development, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Mirati Therapeutics Inc. NA COMPLETED
(Aug 1, 2026)
PHASE3
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Genmab NA TERMINATED
(Aug 1, 2026)
PHASE1, PHASE2
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer M.D. Anderson Cancer Center NA COMPLETED
(Aug 1, 2026)
PHASE1
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) Daiichi Sankyo NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors Bristol-Myers Squibb NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC Sichuan Baili Pharmaceutical Co., Ltd. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations Spectrum Pharmaceuticals, Inc NA SUSPENDED
(Aug 1, 2026)
PHASE3
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers NRG Oncology NA RECRUITING
(Aug 1, 2026)
PHASE2
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest NA COMPLETED
(Aug 1, 2026)
PHASE2
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors OncoC4, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer Jiangsu HengRui Medicine Co., Ltd. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer Dana-Farber Cancer Institute NA RECRUITING
(Aug 1, 2026)
PHASE2
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer University of Illinois at Chicago NA RECRUITING
(Aug 1, 2026)
PHASE2
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) Merus B.V. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3
AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma West China Hospital NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) Daiichi Sankyo NA RECRUITING
(Aug 1, 2026)
PHASE3
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC Relmada Therapeutics, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) Merck Sharp & Dohme LLC NA RECRUITING
(Aug 1, 2026)
PHASE2
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC) Memorial Sloan Kettering Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE3
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer Takeda NA RECRUITING
(Aug 1, 2026)
PHASE3
Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma Case Comprehensive Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE2
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE3
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC CatalYm GmbH NA RECRUITING
(Aug 1, 2026)
PHASE2
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations AstraZeneca NA RECRUITING
(Aug 1, 2026)
PHASE3
Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma Instituto do Cancer do Estado de São Paulo NA RECRUITING
(Aug 1, 2026)
PHASE1
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer Relmada Therapeutics, Inc. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer AstraZeneca NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2
Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma Duke University NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation Genfleet Therapeutics (Shanghai) Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer University of Texas Southwestern Medical Center NA RECRUITING
(Aug 1, 2026)
PHASE1
SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC CSPC Megalith Biopharmaceutical Co.,Ltd. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma Corbus Pharmaceuticals Inc. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer First Affiliated Hospital of Zhejiang University NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. Jiangsu HengRui Medicine Co., Ltd. NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer Jiangsu Alphamab Biopharmaceuticals Co., Ltd NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Shanghai Jiao Tong University School of Medicine NA RECRUITING
(Aug 1, 2026)
PHASE3
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer Wake Forest University Health Sciences NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder Noah Hahn, M.D. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects Royal Marsden NHS Foundation Trust NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer Yale University NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities Wake Forest University Health Sciences NA TERMINATED
(Jul 1, 2026)
PHASE1
Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ Universitätsmedizin Mannheim NA COMPLETED
(Jul 1, 2026)
PHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction Sixth Affiliated Hospital, Sun Yat-sen University NA RECRUITING
(Jul 1, 2026)
PHASE2
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Gilead Sciences NA TERMINATED
(Jul 1, 2026)
PHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors Exelixis NA RECRUITING
(Jul 1, 2026)
PHASE1
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) Hoffmann-La Roche NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) Peking Union Medical College Hospital NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers Washington University School of Medicine NA TERMINATED
(Jul 1, 2026)
PHASE1, PHASE2
Intravesical Gem/Doce in Patients With NMIBC University of Arizona NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NuCana plc NA TERMINATED
(Jul 1, 2026)
PHASE1, PHASE2
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer Seagen, a wholly owned subsidiary of Pfizer NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) Sichuan Baili Pharmaceutical Co., Ltd. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 AstraZeneca NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor OSE Immunotherapeutics NA RECRUITING
(Jul 1, 2026)
PHASE3
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Janssen Research & Development, LLC NA COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) Revolution Medicines, Inc. NA RECRUITING
(Jul 1, 2026)
PHASE3
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma Fudan University NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer STCube, Inc. NA RECRUITING
(Jul 1, 2026)
PHASE2
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy MediLink Therapeutics (Suzhou) Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE3
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment Sichuan Baili Pharmaceutical Co., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE3
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. The University of The West Indies NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial University of Washington NA RECRUITING
(Jul 1, 2026)
PHASE2
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy Multitude Therapeutics Inc. NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2, PHASE3
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Blokhin's Russian Cancer Research Center NA RECRUITING
(Jul 1, 2026)
PHASE2
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Antengene Biologics Limited NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC AstraZeneca NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3
A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study Hospices Civils de Lyon NA COMPLETED
(Jun 1, 2026)
PHASE1
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). Amgen NA COMPLETED
(Jun 1, 2026)
PHASE3
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer Australian and New Zealand Urogenital and Prostate Cancer Trials Group NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy GlaxoSmithKline NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2, PHASE3
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Hospices Civils de Lyon NA COMPLETED
(Jun 1, 2026)
PHASE2
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors Memgen, Inc. NA RECRUITING
(Jun 1, 2026)
PHASE1
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer Akeso NA COMPLETED
(Jun 1, 2026)
PHASE2
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) Polaris Group NA TERMINATED
(Jun 1, 2026)
PHASE3
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer Genelux Corporation NA RECRUITING
(Jun 1, 2026)
PHASE2
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response Canadian Cancer Trials Group NA RECRUITING
(Jun 1, 2026)
PHASE3
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma Abramson Cancer Center at Penn Medicine NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer MediLink Therapeutics (Suzhou) Co., Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE3
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer Sichuan Baili Pharmaceutical Co., Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE3
QLC5508 in Participants With Metastatic Prostate Cancer Qilu Pharmaceutical Co., Ltd. NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE3
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma National Cancer Institute (NCI) NA TERMINATED
(May 1, 2026)
PHASE3
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer NRG Oncology NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer National Cancer Institute (NCI) NA TERMINATED
(May 1, 2026)
PHASE3
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Memorial Sloan Kettering Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Gilead Sciences NA COMPLETED
(May 1, 2026)
PHASE3
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer Genprex, Inc. NA TERMINATED
(May 1, 2026)
PHASE1
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) SWOG Cancer Research Network NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2, PHASE3
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2
Study With Various Immunotherapy Treatments in Participants With Lung Cancer Gilead Sciences NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer MacroGenics NA COMPLETED
(May 1, 2026)
PHASE2
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers Hummingbird Bioscience NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors Vividion Therapeutics, Inc. NA RECRUITING
(May 1, 2026)
PHASE1
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors Shanghai Henlius Biotech NA ENROLLING BY INVITATION
(May 1, 2026)
PHASE1
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Shanghai Hengrui Pharmaceutical Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE3
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy BLATAM NA RECRUITING
(May 1, 2026)
PHASE2
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer Shanghai Henlius Biotech NA RECRUITING
(May 1, 2026)
PHASE2, PHASE3
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(Phase II Study Ongoing) Sinocelltech Ltd. NA NOT YET RECRUITING
(May 1, 2026)
PHASE2
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Hansoh BioMedical R&D Company NA NOT YET RECRUITING
(May 1, 2026)
PHASE3
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Achieve Life Sciences NA COMPLETED
(Apr 1, 2026)
PHASE3
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer Incyte Corporation NA TERMINATED
(Apr 1, 2026)
PHASE2
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer National Cancer Institute (NCI) NA COMPLETED
(Apr 1, 2026)
PHASE2
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BioLite, Inc. NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients Sanofi NA TERMINATED
(Apr 1, 2026)
PHASE3
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma Asan Medical Center NA COMPLETED
(Apr 1, 2026)
PHASE2
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) Centre Francois Baclesse NA COMPLETED
(Apr 1, 2026)
PHASE2
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer National Cancer Center Hospital East NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids Roland Seiler-Blarer NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Gilead Sciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy SWOG Cancer Research Network NA RECRUITING
(Apr 1, 2026)
PHASE3
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma Mayo Clinic NA RECRUITING
(Apr 1, 2026)
PHASE2
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies Arcus Biosciences, Inc. NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) Sichuan Baili Pharmaceutical Co., Ltd. NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma The University of Texas Health Science Center at San Antonio NA TERMINATED
(Apr 1, 2026)
PHASE1, PHASE2
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients Charles Drew University of Medicine and Science NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment BioNTech SE NA RECRUITING
(Apr 1, 2026)
PHASE2
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) Sichuan Baili Pharmaceutical Co., Ltd. NA RECRUITING
(Apr 1, 2026)
PHASE3
Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer Akeso NA RECRUITING
(Apr 1, 2026)
PHASE3
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure Hansoh BioMedical R&D Company NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC Michael A. O'Donnell NA RECRUITING
(Apr 1, 2026)
PHASE2
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer Rutgers, The State University of New Jersey NA RECRUITING
(Apr 1, 2026)
PHASE2
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma Qilu Pharmaceutical Co., Ltd. NA RECRUITING
(Apr 1, 2026)
PHASE3
SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma CSPC Megalith Biopharmaceutical Co.,Ltd. NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE3
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure Tianjin Medical University Cancer Institute and Hospital NA RECRUITING
(Apr 1, 2026)
PHASE2
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer Shanghai JMT-Bio Inc. NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2
Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma Yonsei University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency Peter Hosein, MD NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2
Radium-223 in Biochemically Recurrent Prostate Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Mar 10, 2026)
PHASE2
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer Dana-Farber Cancer Institute NA COMPLETED
(Mar 1, 2026)
PHASE1
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery National Cancer Institute (NCI) NA COMPLETED
(Mar 1, 2026)
PHASE1
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors Conjupro Biotherapeutics, Inc. NA TERMINATED
(Mar 1, 2026)
PHASE1
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). Merck Sharp & Dohme LLC NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE3
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer University of Florida NA RECRUITING
(Mar 1, 2026)
PHASE2
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer H. Lee Moffitt Cancer Center and Research Institute NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) Second Xiangya Hospital of Central South University NA RECRUITING
(Mar 1, 2026)
PHASE2
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer Shanghai Henlius Biotech NA RECRUITING
(Mar 1, 2026)
PHASE2, PHASE3
A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT Relmada Therapeutics, Inc. NA WITHDRAWN
(Mar 1, 2026)
PHASE3
ctDNA in HER2+ EBC Neoadjuvant Treatment Shanghai Jiao Tong University School of Medicine NA RECRUITING
(Mar 1, 2026)
PHASE2




Generic Launch

Generic Release Date:

Taxotere's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 22, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Taxotere Generic API suppliers:

Docetaxel is the generic name for the brand Taxotere. 16 different companies have already filed for the generic of Taxotere, with Mylan Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Taxotere's generic

How can I launch a generic of Taxotere before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Taxotere's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Taxotere's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Taxotere -

Strength Submission Date Expiration Date of Last Qualifying Patent 180-Day Status First Applicant Approval Generic Competition Status
25 mg / 5 mL
🔒 Unlock
30 Jun, 2009 22 Nov, 2013 Extinguished Less


Alternative Brands for Taxotere

Taxotere which is used for treating hypertension and congestive heart failure., has several other brand drugs using the same active ingredient (Docetaxel). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Avyxa Holdings
Docivyx
Shilpa
Docetaxel
Zhuhai
Beizray


Apart from brand drugs containing the same ingredient, some generics have also been filed for Docetaxel, Taxotere's active ingredient. Check the complete list of approved generic manufacturers for Taxotere





About Taxotere

Taxotere is a drug owned by Sanofi Aventis Us Llc. It is used for treating hypertension and congestive heart failure. Taxotere uses Docetaxel as an active ingredient. Taxotere was launched by Sanofi in 2010.

Approval Date:

Taxotere was approved by FDA for market use on 03 August, 2010.

Active Ingredient:

Taxotere uses Docetaxel as the active ingredient. Check out other Drugs and Companies using Docetaxel ingredient

Treatment:

Taxotere is used for treating hypertension and congestive heart failure.

Dosage:

Taxotere is available in injectable form for injection use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE Discontinued INJECTION
80MG/4ML (20MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE Discontinued INJECTION
20MG/ML (20MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE Discontinued INJECTION